Methods of treatment involving the protease for activating...

Details Methods of treatment involving the protease for activating... Methods of treatment involving the protease for activating...

2011-02-01

2011-02-01

Szperka, Michael (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013700, C514S014600, C514S014900

Reexamination Certificate

active

07879803

ABSTRACT:
This application describes methods of treatment involving a protease for activating the blood clotting factor VII, which (a) activates blood clotting factor VII, (b) is inhibited by the presence of aprotinin, (c) is increased in its activity by the presence of at least one of the following: calcium ions, heparin, or heparin related substances, and (d) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more bands in the molecular weight range from 50 to 75 kDa, and in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa, and a band, which corresponds to a proenzyme, in the molecular weight range from 60 to 65 kDa.

REFERENCES:
patent: 4363319 (1982-12-01), Altshuler
patent: 4447412 (1984-05-01), Bilton
patent: 5175087 (1992-12-01), Ranby et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 6359054 (2002-03-01), Lemieux et al.
patent: 6528299 (2003-03-01), Roemisch et al.
patent: 7153679 (2006-12-01), Kiechl et al.
patent: 2002/0110552 (2002-08-01), Roemisch et al.
patent: 2003/0077271 (2003-04-01), Roemisch et al.
patent: 2003/0124622 (2003-07-01), Roemisch et al.
patent: 2003/0215447 (2003-11-01), Roemisch et al.
patent: 2004/0063187 (2004-04-01), Roemisch et al.
patent: 2004/0186277 (2004-09-01), Roemisch et al.
patent: 2005/0032109 (2005-02-01), Roemisch et al.
patent: 2 504 921 (1982-05-01), None
patent: WO 91/01497 (1991-02-01), None
patent: WO 9306855 (1993-04-01), None
patent: WO 96/10638 (1996-04-01), None
Kazama, Yoshiaki et al., “Hepsin, a Putative Membrane-Associated Serine Protease, Activates Human Factor VII and Initiates a Pathway of Blood Coagulation on the Cell Surface Leading to Thrombin Formation,”The Journal of Biological Chemistry, vol. 270 (1), pp. 66-72, (1995).
Choi-Miura, Nam-Ho et al., “Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) From Human Plasma: It Has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator,”J. Biochem, vol. 119 (6), pp. 1157-1165 (1996).
Laake, K. et al., “Activation of Purified Plasma Factor VII by Human Plasmin, Plasma Kallikrein, And Activated Components of the Human Intrinsic Blood Coagulation System,”Thrombosis Research, vol. 5 (6), pp. 759-772 (1974).
Römisch, J. et al., “A Protease Isolated From Plasma Which Activates FVII in a Tissue Factor Independent Manner But Inactivates FV and FVII I,” Annals of Hematology, vol. 78 (1), pp. 24-27 (1999) (Abstract).
Römisch, J. et al., “The FVII Activating Protease Mediates Fibrinolytic Effects Activating Single-Chain Plasminogen Activators,”Annals of Hematology, vol. 78 (1), pp. 24-27 (1999) (Abstract).
Hunfeld, A. et al., “Identification of the Thrombin-Like Activity of PCCs,”Annals of Hematology, vol. 76 (1), pp. 25-28 (1998) (Abstract).
Etscheid et al., 43rdAnnual Meeting of the GTH; Supplement 1 to vol. 78 A42, P030 (1999).
Hunfeld et al., 42ndAnnual Meeting of the GTH; Supplement 1 to vol. 76 A101, P294 (1998).
Hunfeld et al., 41stAnnual Meeting of the GTH; Supplement 1 to vol. 74 A87 P113 (1997).
Römisch et al., 43rdAnnual Meeting of the GTH; Supplement 1 to vol. 78 A24, FV079 (1999).
Römisch et al., 43'd Annual Meeting of the GTH; Supplement 1 to vol. 78 A10, FV024 (1999).
Hirsh et al., “Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing information, monitoring, efficacy, and safety,”Chest114(Suppl. 5): 489S-510S (1998).
N. Kitamura, GenBank accession D49742 (1995).
K. Hashimoto et al., “Cloning of the cDNA for a Mouse Homologue of Human PHBP: a Novel HyaluronanBinding Protein,”Biol. Pharm. Bulletin, vol. 20 (11): 1127-1130 (1997).
J-I. Sumiya et al., “Isolation and Characterization of the Plasma Hyaluronan-Binding Protein (PHBP) Gene (HABP2),”J. Biochem., vol. 122: 983-990 (1997).
A. Zhukov et al., “Purification and characterization of hepsin from rat liver microsomes,”Biochimica et Biophysica Acta, vol. 1337: 85-95 (1997).
A. Hunfeld et al., “Detection of a novel plasma serine protease during purification of vitamin K-dependent coagulation factors,”FEBSLetters, vol. 1 (456): 290-294 (1999).
J. Roemisch et al., “A Protease Isolated From human plasma activating Factor VII independent of tissue factor,”Blood Coagulation and Fibrinolysis, vol. 10 (8): 471-479 (1999).
A. Vostrov et al., “Plasma Hyaluronan-binding Protein Is a Serine Protease,”J. Biological Chemistry, vol. 275 (30): 22978-22985 (2000).
J. Roemisch et al., “Factor VII Activating Protease (FSAP): A Novel Protease in Hemostasis,”Biol. Chem., 383: 1119-1124 (2002).

Affiliated with

Also associated with

Rating

Methods of treatment involving the protease for activating... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment involving the protease for activating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment involving the protease for activating... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2637136